PEGylation of interferon α2 improves lymphatic exposure after subcutaneous and intravenous administration and improves antitumour efficacy against lymphatic breast cancer metastases-Reference-Cited by-同舟云学术

PEGylation of interferon α2 improves lymphatic exposure after subcutaneous and intravenous administration and improves antitumour efficacy against lymphatic breast cancer metastases

Published:2013-06 Issue:2 Volume:168 Page:200-208
ISSN:0168-3659
Container-title:Journal of Controlled Release
language:en
Short-container-title:Journal of Controlled Release

Author:

Kaminskas Lisa M.,Ascher David B.,McLeod Victoria M.,Herold Marco J.,Le Caroline P.,Sloan Erica K.,Porter Christopher J.H.

Funder

Samuel Nissen Charitable Foundation

NHMRC Career Development fellowship

National Breast Cancer Foundation fellowship

NIH

NHMRC

Victorian Government Operational Infrastructure Support Scheme

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference33 articles.

1. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease;Pantaleo;Nature,1993

2. Lymph node micrometastases from breast carcinoma: reviewing the dilemma;Dowlatshahi;Cancer,1997

3. Immunopathogenesis of lymphatic filarial disease;Babu;Semin. Immunopathol.,2012

4. Infections of the Lymphatic System: Primer of Tropical Medicine;Melrose,2005

5. Drug concentrations in axillary lymph nodes after lymphatic chemotherapy on patients with breast cancer;Chen;Breast Cancer Res.,2004

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preparation of GSH-responsive nanoparticles for combined chemo-photothermal therapy codelivering 6-MP and Ce6;Journal of Drug Delivery Science and Technology;2024-03

2. Structure and modification;Fibroblast Growth Factors;2024

3. Leveraging Lymphatic System Targeting in Systemic Lupus Erythematosus for Improved Clinical Outcomes;Pharmacological Reviews;2023-12-13

4. Type of anesthesia for cancer resection surgery: No differential impact on cancer recurrence in mouse models of breast cancer;PLOS ONE;2023-11-27

5. Dose-Dependent Production of Anti-PEG IgM after Intramuscular PEGylated-Hydrogenated Soy Phosphatidylcholine Liposomes, but Not Lipid Nanoparticle Formulations of DNA, Correlates with the Plasma Clearance of PEGylated Liposomal Doxorubicin in Rats;Molecular Pharmaceutics;2023-05-31